Targeting the oncogene LSF with either the small molecule inhibitor FQI1 or siRNA causes mitotic delays with unaligned chromosomes, resulting in cell death or senescence

BACKGROUND: The oncogene LSF (encoded by TFCP2) has been proposed as a novel therapeutic target for multiple cancers. LSF overexpression in patient tumors correlates with poor prognosis in particular for both hepatocellular carcinoma and colorectal cancer. The limited treatment outcomes for these di...

Descripción completa

Detalles Bibliográficos
Autores principales: Willoughby, Jennifer L. S., George, Kelly, Roberto, Mark P., Chin, Hang Gyeong, Stoiber, Patrick, Shin, Hyunjin, Pedamallu, Chandra Sekhar, Schaus, Scott E., Fitzgerald, Kevin, Shah, Jagesh, Hansen, Ulla
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7296649/
https://www.ncbi.nlm.nih.gov/pubmed/32539694
http://dx.doi.org/10.1186/s12885-020-07039-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7296649/
https://www.ncbi.nlm.nih.gov/pubmed/32539694
http://dx.doi.org/10.1186/s12885-020-07039-1

Ejemplares similares